Novo Nordisk A/S (NYSE:NVO) Shares Sold by Kingswood Wealth Advisors LLC

Kingswood Wealth Advisors LLC cut its position in Novo Nordisk A/S (NYSE:NVO) by 75.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,822 shares of the company’s stock after selling 27,208 shares during the quarter. Kingswood Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $759,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S during the second quarter worth approximately $25,000. Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S during the 3rd quarter worth $28,000. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S in the third quarter valued at $42,000. Albion Financial Group UT raised its holdings in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after buying an additional 278 shares during the last quarter. Finally, Sound Income Strategies LLC boosted its stake in shares of Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after buying an additional 243 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on NVO. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Down 1.3 %

Shares of Novo Nordisk A/S stock opened at $84.05 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The business has a 50 day moving average price of $94.75 and a 200 day moving average price of $114.02. The company has a market capitalization of $377.17 billion, a P/E ratio of 27.20, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.